All In Biotech

Drug Trial Radar · NCT07148843

Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

105

Planned (sponsor's estimate)

Start

Oct 21, 2026

Primary completion

Oct 31, 2030

Study completion Oct 31, 2030

Sponsor

Lead sponsor
Johns Hopkins UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
First posted
Aug 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 21 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cannabidiol (CBD), one of the most prevalent cannabinoids in cannabis (marijuana) has been shown to reduce alcohol withdrawal symptoms in laboratory animals. In people without alcohol use disorder (AUD), CBD has been show to be effective in reducing anxiety, sleep problems, and seizures; all of these are common symptoms of alcohol withdrawal. This randomized placebo-controlled clinical trial will evaluate the potential of CBD to improve alcohol withdrawal symptoms and reduce craving during acute abstinence among individuals with moderate-to-severe AUD. Adult participants with moderate-to-severe AUD will be admitted to an inpatient research unit at the Johns Hopkins Hospital for a 5-day, 4-night stay that includes alcohol abstinence with management of their alcohol withdrawal. In addition to standard care, participants will receive CBD or placebo (no CBD), complete assessments of withdrawal, sleep quality and provide breath and blood samples.

Conditions

  • Alcohol Use Disorder (AUD)
  • Withdrawal From Addictive Substance; Detoxification
  • Craving

Interventions

  • Cannabidiol (CBD)Drug

    Cannabidiol

  • PlaceboDrug

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak score on the Alcohol Withdrawal Symptom Checklist (AWSC)Time frame: Four times daily during inpatient stay (4 nights)
  2. Peak score on the Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar)Time frame: 4 times daily during inpatient stay (4 nights)
  3. Average total sleep time (minutes) and wake after sleep onset as measured by wrist actigraphyTime frame: 4 nights during inpatient stay
  4. Peak alcohol craving as measured by scores on the Alcohol Urge Questionnaire (AUQ)Time frame: Four times daily during inpatient stay (4 nights)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Behavioral Pharmacology Research Unit

    Baltimore, Maryland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.